registrational trial

Related by string. registrational trials * : 3 registrational trial . registrational clinical . registrational studies . registrational Phase . Phase III registrational . registrational / trialed . trialing . trials . Trials . TRIAL . Trial : Phase III clinical trials . Week Premium Trial . Phase III trials . placebo controlled clinical trials . randomized controlled trial * *

Related by context. All words. (Click for frequent words.) 75 registrational 74 Phase IIb trials 74 SUCCEED trial 72 phase IIb clinical 72 IMA# 72 forodesine 72 elotuzumab 72 Personalized Immunotherapy 72 phase IIb trial 71 alvespimycin 71 Phase Ib study 71 Phase 2a trial 71 randomized controlled Phase 71 lintuzumab 71 Amigal 71 oral ridaforolimus 71 INCB# [001] 71 AEG# 71 ELACYT 70 Phase IIb clinical trials 70 3 registrational trial 70 multicenter Phase 70 GALNS 70 Phase IIa trial 70 generation purine nucleoside 70 phase Ib 70 Archexin 70 Elagolix 70 sapacitabine 70 satraplatin Phase 69 R#/MEM # 69 Phase 2b Clinical Trial 69 FOLOTYN ® 69 Troxatyl 69 LymphoStat B belimumab 69 confirmatory Phase III 69 Phase #/#a trial 69 IIa trial 69 Phase 2b clinical 69 phase IIb 69 Plicera 69 HGS ETR1 69 Pivotal Phase 69 PNP inhibitor 69 LUX Lung 69 Phase 2b trial 69 placebo controlled Phase 69 Phase 2b study 69 Phase III Clinical Trial 69 Phase Ib 69 Amrubicin 69 Glufosfamide 69 Phase 2a clinical 69 TRO# 69 Phase IIIb clinical 69 EDEMA3 69 Pivotal Trial 69 Allovectin 7 68 OvaRex R 68 Metastatic Melanoma 68 EOquin TM 68 Panzem R NCD 68 TACI Ig 68 PANVAC VF 68 assessing T DM1 68 antibody MAb 68 Ozarelix 68 HER2 positive metastatic breast 68 TMC# [002] 68 Cloretazine ® 68 Bezielle 68 Ixempra 68 Phase #b/#a clinical 68 investigational humanized monoclonal antibody 68 BRIM2 68 multicenter Phase II 68 Ocrelizumab 68 EndoTAG TM -1 68 Xanafide 68 Phase 1b 68 EDEMA4 68 CR# vcMMAE 68 phase IIb study 68 relapsed refractory multiple myeloma 68 randomized Phase 68 Phase Ib II 68 Phase Ib clinical trials 68 Phenoptin 68 ozarelix 68 glufosfamide 68 Randomized Phase 68 mGluR5 negative 68 MyVax R 68 dose escalation Phase 68 randomized Phase III 68 Phase Ib clinical 68 CTAP# Capsules 68 refractory chronic lymphocytic 68 elacytarabine 68 Phase 1a clinical 68 TBC# 68 Annamycin 68 phase IIa clinical 68 ATL# [001] 68 HuMax EGFr 68 otelixizumab 68 Tesetaxel 68 Phase 1b trial 67 leading oral taxane 67 axitinib 67 oral prodrug 67 Zenvia ™ 67 SPRYCEL ® 67 HCD# [002] 67 dasatinib Sprycel ® 67 dirucotide 67 pivotal Phase III 67 Panzem R 67 MEK inhibitor RDEA# 67 MEND CABG II 67 Initiate Phase 67 Phase IIb trial 67 MAGE A3 ASCI 67 IRX 2 67 Phase #b/#a trial 67 pivotal Phase 67 Fodosine 67 lintuzumab SGN 67 PEG SN# 67 BAY #-# 67 Daclizumab 67 Aflibercept 67 rALLy clinical trial 67 phase IIa 67 ospemifene 67 deforolimus 67 diarrhea predominant irritable 67 Allovectin 7 R 67 PRTX 67 pertuzumab 67 Hsp# Inhibitor 67 BRIM3 67 CYT# potent vascular disrupting 67 IL# PE#QQR 67 Tanespimycin 67 PDE4 inhibitor 67 Phase 2b 67 obatoclax 67 KNS # 67 Phase #/#a 67 evaluating tivozanib 67 TLK# 67 Phase IIb clinical 67 huC# DM4 67 Quinamed 67 JAK1 67 phase 2a 67 ganetespib 67 mRCC 67 Phase IIa trials 67 Azedra 67 receptor tyrosine kinase inhibitor 67 HGS# 67 CRMD# 67 MKC# MT 67 pharmacokinetic PK study 67 omacetaxine mepesuccinate 66 NO# [002] 66 Evoltra ® 66 Ceflatonin 66 DermaVir Patch 66 HCV protease inhibitor 66 velafermin 66 metastatic renal cell 66 rFVIIIFc 66 Ophena TM 66 Safinamide 66 PEG PAL 66 blinatumomab 66 APPRAISE 66 Dacogen injection 66 Laquinimod 66 custirsen 66 ALN PCS 66 Aplidin 66 PROVENGE sipuleucel T 66 Pivotal Phase III 66 Mipomersen 66 PXD# 66 HGS ETR2 66 orally bioavailable 66 cutaneous T cell 66 anticancer compound 66 trastuzumab DM1 T DM1 66 Vicriviroc 66 PROVENGE ® 66 Clolar ® 66 Phase 2a 66 dose escalation clinical 66 Phase IIb Trial 66 Nexavar ® 66 confirmatory Phase 3 66 Pivotal Study 66 Randomized Phase II 66 Genz # 66 Zerenex 66 Successfully Completes Phase 66 enzastaurin 66 Meets Primary Endpoint 66 cell lymphoma CTCL 66 Clinical Trial Results 66 CIMZIA TM 66 Telatinib 66 MEK inhibitor 66 Phase III pivotal 66 budesonide foam 66 JAK inhibitor 66 histone deacetylase HDAC inhibitor 66 sunitinib malate 66 orally administered inhibitor 66 crizotinib PF # 66 novel VDA molecule 66 immunotherapeutic agent 66 II Clinical Trial 66 adecatumumab 66 GVAX R 66 Denufosol 66 HuMax CD4 66 rNAPc2 66 ZYBRESTAT fosbretabulin 66 Virulizin ® 66 refractory cutaneous T 66 APEX PD 66 pharmacokinetic PK 66 Phase 2b clinical trials 66 BLA submission 66 Phase III Clinical Trials 66 TPI ASM8 66 Pralatrexate 65 lorvotuzumab mertansine 65 Alzhemed TM 65 Pharmacokinetics PK 65 Phase 1b clinical trials 65 Campath alemtuzumab 65 neratinib 65 ixabepilone 65 VEGFR2 inhibitor 65 Omacetaxine 65 farletuzumab 65 Cloretazine R VNP#M 65 Allovectin 7 ® 65 Proxinium TM 65 virus HCV protease inhibitor 65 AVASTIN 65 docetaxel chemotherapy 65 evaluating T DM1 65 pediatric acute lymphoblastic 65 refractory gout 65 Phase #b/#a 65 BENLYSTA TM 65 dosing cohort 65 tanespimycin 65 sodium glucose cotransporter 65 investigational pan BCR 65 Phase III clinical 65 LymphoStat B 65 including eniluracil ADH 65 ruxolitinib 65 mitogen activated ERK kinase 65 Tasimelteon 65 Trial Evaluating 65 PSMA ADC 65 Tarvacin TM 65 Phase III randomized controlled 65 Neuvenge 65 generation NNRTI 65 REVIVE Diabetes 65 Phase III Trial 65 EOquin 65 severe hypercholesterolemia 65 Cloretazine 65 Combination REOLYSIN R 65 pomalidomide 65 liposomal formulation 65 Initiated Phase 65 TELINTRA 65 RhuDex ® 65 abiraterone acetate 65 Phase IIb Clinical Trial 65 zanolimumab 65 dose escalation trial 65 metastatic castration resistant 65 TELCYTA 65 ponatinib 65 non nucleoside inhibitor 65 Phase III Pivotal 65 metastatic hormone refractory 65 Prostate AdenoCarcinoma Treatment 65 TMC# C# 65 ALN TTR 65 autologous cellular immunotherapy 65 Azixa 65 dose cohort 65 tolevamer 65 peginesatide 65 oral deforolimus 65 vemurafenib 65 Dapagliflozin 65 Genasense ® 65 randomized Phase 2b 65 IMPACT IMmunotherapy 65 BLA filing 65 PROMACTA 65 bardoxolone 65 Degarelix 65 huN# DM1 65 docetaxel Taxotere R 65 hypoxia activated prodrug 65 Ambrisentan 65 Insegia 65 vidofludimus 65 dextromethorphan quinidine 65 compound INCB# 65 Tyrima 65 MDV# 65 R# #mg BID 65 CINQUIL 65 LibiGel Phase III 65 NVA# 65 HDAC Inhibitor 65 OncoVEX GM CSF 65 OMAPRO 65 Carfilzomib 65 Fx #A 65 sorafenib tablets 65 IMC A# 65 Pirfenidone 65 evaluating satraplatin 65 Tarceva TM 65 systemic anaplastic large 65 Phase Ib IIa 65 EDEMA3 trial 65 investigational compound 65 AZD# 65 hormone refractory prostate cancer 65 interferon gamma 1b 65 novel histone deacetylase 65 MAA submission 65 investigational monoclonal antibody 65 Phase IIIb 65 allosteric modulator NAM 65 PDX pralatrexate 65 relapsed multiple myeloma 65 PROSTVAC TM 65 personalized immunotherapy 65 Phase 1b clinical 65 trastuzumab DM1 65 SinuNase TM 65 Pafuramidine 65 Temsirolimus 65 baminercept 65 trabedersen 65 Cutaneous T 64 UPLYSO 64 VitiGam 64 randomized Phase IIb 64 castrate resistant prostate cancer 64 Azedra TM 64 NPC 1C 64 Bosutinib 64 AAG geldanamycin analog 64 Virulizin R 64 Blinatumomab 64 AP# [003] 64 ZACTIMA 64 CCR5 antagonist 64 regorafenib 64 BENLYSTA ® 64 HCV SPRINT 64 XL# anticancer compounds 64 HRPC 64 Pimavanserin 64 Genasense ® oblimersen 64 Alocrest 64 LymphoStat B TM 64 ThermoDox R 64 mCRC patients 64 TRANSFORMS 64 ABSORB trial 64 Perifosine 64 PLK1 SNALP 64 Locteron ® 64 eprotirome 64 GAMMAGARD 64 aflibercept 64 unique alkylating agent 64 Pertuzumab 64 Apoptone 64 Voreloxin 64 cutaneous T 64 SAR# [004] 64 castration resistant prostate cancer 64 MBP# [001] 64 BENLYSTA ™ 64 Icatibant 64 talactoferrin 64 AVONEX ® 64 RG# [001] 64 oral taxane 64 multicenter Phase III 64 MGCD# [001] 64 PRT# 64 vascular disrupting agent 64 epigenetic therapies 64 Phase III 64 antibody MT# 64 midstage trials 64 afatinib 64 RhuDex TM 64 EFAPROXYN 64 Diamyd ® 64 CHAMPION PCI 64 imatinib Gleevec ® 64 rALLy 64 acyclovir Lauriad R 64 R sorafenib tablets 64 nab paclitaxel 64 eniluracil 64 polymerase inhibitor 64 Asentar 64 ANCHOR trial 64 Prednisone Against Refractory 64 ocrelizumab 64 multicenter phase 64 ofatumumab 64 targeted radiotherapeutic 64 CCX# B 64 BCX# 64 valopicitabine 64 Phase 2b Trial 64 Azacitidine 64 EndoTAGTM 1 64 HQK 64 Kamada AAT 64 GetGoal Phase III 64 selective androgen receptor modulator 64 oral picoplatin 64 lymphoma CTCL 64 Factor VIIa 64 XmAb# 64 Cetrorelix 64 pan HDAC inhibitor 64 ongoing Phase 1b 64 cilengitide 64 GLP toxicology studies 64 Corlux 64 mGluR5 NAM 64 Serdaxin 64 Initiate Clinical Trial 64 Phase 1a 64 mertansine 64 inhaled liposomal ciprofloxacin 64 Irinotecan 64 Phase IIa clinical 64 Traficet EN 64 CTA# Injection 64 BiovaxID TM 64 placebo controlled Phase III 64 depsipeptide 64 IMC #B 64 isoform selective 64 Triapine 64 Telintra 64 STRIDE PD 64 ThGRF 64 multicenter randomized placebo controlled 64 epothilone 64 MAXY alpha 64 Aryplase 64 evaluating picoplatin 64 ofatumumab HuMax CD# 64 CCR9 antagonist 64 follicular non 64 torezolid phosphate 64 Capesaris 64 Nuvion 64 Phase 2a Study 64 Sym# 64 DPX Survivac 64 recurrent NSCLC 64 Phase 2a Clinical Trial 64 Phase IIB 64 SUTENT 64 metastatic CRC 64 Hedgehog Pathway Inhibitor 64 apricitabine ATC 64 2 methoxyestradiol 64 PEGylated interferon beta 1a 64 OvaRex ® MAb 64 ASA# 64 PEGylated Fab fragment 64 Ofatumumab 64 belinostat 64 Vicinium TM 64 StemEx R 64 beta 1a 64 Immunotherapeutic 64 Abiraterone acetate 64 lumiliximab 64 PS# [001] 64 ALN TTR# 64 daclizumab 64 celgosivir 64 Bafetinib 64 cangrelor 64 Xcytrin R 64 clinical pharmacology studies 64 thymalfasin 64 RSD# oral 64 TKM ApoB 64 IND submission 63 Achieves Primary Endpoint 63 APTIVUS 63 Brentuximab Vedotin SGN 63 Aurexis 63 Phase lll 63 TREANDA 63 ACTEMRA TM 63 PD LID 63 initiated Phase Ib 63 Onalta ™ 63 veltuzumab 63 seliciclib CYC# 63 multiple myeloma MM 63 ORENCIA ® 63 DEB# 63 Sapacitabine 63 Phase III trials 63 IMGN# 63 unresectable stage 63 TNFerade ™ 63 MT#/MEDI-# 63 multi kinase inhibitor 63 RezularTM 63 Telbivudine 63 Vitaxin 63 Ceflatonin R 63 GV# [001] 63 trastuzumab Herceptin R 63 RhuDex R 63 radiation sensitizer 63 novel synthetic PEGylated 63 phase Ib clinical 63 Dasatinib 63 palifosfamide Zymafos TM 63 MT# MEDI 63 Bicifadine 63 KIACTA ™ 63 multicentre randomized 63 TELINTRA R 63 GOUT 63 Oral NKTR 63 formerly LymphoStat B 63 CDK inhibitor 63 comparing alemtuzumab 63 Dose Ranging Study 63 leukemia AML 63 Cimzia TM 63 ONCONASE R 63 Prospective Randomized 63 CLARITY study 63 Granted Orphan Drug 63 Urocidin 63 leukemia CLL 63 generation antisense inhibitor 63 viral kinetic 63 Phase 2a clinical trials 63 Phase III randomized 63 JZP 63 Epratuzumab 63 Symadex 63 figitumumab 63 vicriviroc 63 oncolytic virus therapies 63 L BLP# 63 KRN# 63 previously untreated follicular 63 brivaracetam 63 plus gemcitabine 63 Golimumab 63 CoFactor 63 Fludara ® 63 GRN# 63 Hepatocellular Carcinoma HCC 63 ® natalizumab 63 selective modulator 63 CEQ# 63 Completes Patient Enrollment 63 generation URAT1 inhibitor 63 QNEXA 63 First Patient Dosed 63 Romiplostim 63 Marqibo 63 Fibrillex TM 63 pralatrexate injection folate analogue 63 alvimopan 63 Surfaxin LS 63 Prodarsan R 63 Tavocept 63 tramiprosate Alzhemed TM 63 Romidepsin 63 brentuximab vedotin SGN 63 metastatic HRPC 63 investigational antiplatelet agent 63 OHR/AVR# 63 Hodgkin lymphoma HL 63 ALN VSP Phase 63 metastatic sarcomas 63 Anturol TM 63 corticosteroid dexamethasone 63 includes TOLAMBA TM 63 pralatrexate 63 cell chronic lymphocytic 63 BCIRG 63 SCIB1 63 relapsing multiple sclerosis 63 Topline Results 63 severe gastroparesis 63 ToGA 63 StemEx 63 IAP inhibitor 63 fosbretabulin 63 ATL/TV# 63 relapsed MM 63 urocortin 2 63 Deforolimus 63 Tezampanel 63 Clevudine 63 CALGB 63 mipomersen 63 tremelimumab 63 Zenvia TM 63 tiapamil 63 AZILECT R 63 sorafenib Nexavar 63 glucokinase activator 63 advanced carcinoid 63 CD3 monoclonal antibody 63 Phase IIb III 63 Xcellerated T Cells 63 metaglidasen 63 gefitinib Iressa 63 rFIXFc 63 ZYBRESTAT 63 Ganite ® 63 panitumumab 63 vosaroxin 63 product candidate Lpathomab 63 HuLuc# 63 VELCADE melphalan 63 prGCD 63 maximally tolerated dose 63 alemtuzumab Campath 63 CCX# 63 Spiegelmer ® 63 OMAPRO ™ 63 Ceflatonin ® 63 evaluating REVLIMID 63 Hedgehog antagonist 63 Panzem 63 vandetanib 63 trastuzumab emtansine T DM1 63 resminostat 63 humanized anti 63 Study Evaluating 63 YONDELIS 63 PI3K/Akt pathway inhibitor 63 lomitapide 63 multiple ascending dose 63 delivers fluocinolone acetonide FA 63 NOX E# 63 Oral Fingolimod 63 Reverset 63 Pruvel 63 XYOTAX TM 63 PKC# 63 Uvidem 63 cystinosis patients 63 5 fluorouracil leucovorin 63 DXL# 63 PF # [001] 63 individualized cellular immunotherapy 63 Curaxin CBLC# 63 tesmilifene 63 temsirolimus 63 MEK Inhibitor 63 perifosine 63 Cethromycin 63 Ophena 63 placebo controlled clinical 63 dirucotide MBP# 63 dasatinib 63 recurrent glioblastoma multiforme 63 pain palliation 63 bendamustine 63 PEGINTRON TM 63 PRECISE trial 63 phase IIIb 63 AEGR 63 CCR5 mAb 63 generation PNP inhibitor 63 Alemtuzumab 63 Azilect ® 63 dimebon latrepirdine 63 Epothilone D 63 EGFR TKI 63 PROSTVAC ® 63 Bayer HealthCare Onyx Pharmaceuticals 63 ProLindac 63 GRN#L 63 gemcitabine Gemzar ® 63 class mGluR5 inhibitor 63 TroVax ® 63 CBLC# 63 Relapsed Refractory 62 evaluating mipomersen 62 targeting CD# 62 eltrombopag 62 sunitinib 62 Phase IIIb study 62 systemic ALCL 62 OXi# 62 low dose cytarabine 62 OMP #R# 62 Zoraxel 62 Phase III Trials 62 dasatinib Sprycel 62 Rigel R# 62 Belinostat 62 lupus nephritis 62 AIMM trial 62 PF # [002] 62 TOCOSOL Paclitaxel 62 ularitide 62 volociximab 62 compound AEZS 62 teriflunomide 62 PrevOnco ™ 62 Clolar 62 nucleoside analog 62 Xeloda ® 62 evaluating Actimmune 62 orBec 62 Phase III clinical trials 62 SNT MC# 62 HspE7 62 Novolimus 62 Viramidine 62 metastatic castrate resistant 62 BrachySil TM 62 Intravenous CP 62 CIMZIA TM certolizumab pegol 62 CA4P 62 Phase IIb 62 pradefovir 62 non nucleoside HCV 62 riociguat 62 INSPIRE Trial Phase III 62 bosutinib 62 ocular formulation 62 Iloperidone 62 dependent kinase inhibitor 62 Syncria 62 candidate deforolimus 62 FOLFOX6 chemotherapy regimen 62 mTOR inhibitor 62 TEMSO 62 candidate AQ4N 62 octreotide implant 62 oncolytic vaccine 62 Metastatic Colorectal Cancer 62 Inhalation Solution 62 refractory AML 62 FOLOTYN 62 IRESSA 62 Multiple Ascending Dose 62 dose escalation study 62 metastatic colorectal 62 Onco TCS 62 INCB# [002] 62 label multicenter Phase 62 Adjuvant Treatment 62 cancer neuroendocrine tumor 62 PSN# [002] 62 non metastatic osteosarcoma 62 Taxotere ® 62 UVIDEM 62 vaccines oncolytic virus 62 AQ4N 62 TKB# 62 next generation URAT1 62 biliary tract cancer 62 SinuNase ™ 62 erlotinib Tarceva ® 62 Iluvien ® 62 #D#C# 62 Bortezomib 62 Solazed TM 62 Civacir 62 pegylated interferons 62 Acute Myeloid Leukemia AML 62 ProSavin 62 treatment naive genotype 62 ZOLINZA 62 IgG1 monoclonal antibody 62 R lenalidomide 62 SCCHN 62 TRISENOX 62 davunetide intranasal AL 62 mapatumumab 62 oral ghrelin agonist 62 SPIRIT FIRST 62 confirmatory clinical 62 LHRH receptor positive 62 BRAF inhibitor 62 Testosterone MDTS ® 62 ritonavir boosted danoprevir 62 MabCampath 62 romidepsin 62 ara C 62 nalbuphine ER 62 Campath ® 62 Trastuzumab DM1 62 maturation inhibitor 62 Imprime PGG 62 TG# [003] 62 Microplasmin 62 inhaled formulation 62 pseudobulbar affect PBA 62 pegylated interferon alpha 62 RDEA# 62 Drug Eluting Stent System 62 Advanced Renal Cell 62 rilonacept 62 AzaSite Plus 62 dose cohorts 62 Exelixis XL# 62 label multicenter 62 maribavir 62 Omigard 62 Desmoteplase 62 TRX1 62 Tesmilifene 62 essential thrombocythemia ET 62 Satraplatin 62 R roscovitine 62 JAK2 inhibitor 62 Octreolin 62 refractory metastatic 62 BiTE R 62 Afatinib 62 telomerase therapeutic 62 luteinizing hormone releasing 62 efaproxiral 62 hormone LHRH antagonist 62 induced macular edema 62 IV NSCLC 62 PRE SURGE 62 PNT# 62 European Sepsis Trial 62 plus prednisone 62 Phase III confirmatory 62 entinostat 62 tezampanel 62 registrational Phase 62 tubulin inhibitor 62 Motesanib 62 Torisel 62 Recombinant Human 62 SUTENT ® 62 LE SN# 62 Copegus ribavirin 62 opioid induced bowel dysfunction 62 double blinded placebo 62 refractory acute myeloid 62 ZK EPO 62 Amigal TM 62 Zenvia Phase III 62 laquinimod 62 CD# CEA 62 Febuxostat 62 oral proteasome inhibitor 62 cetuximab Erbitux R 62 adecatumumab MT# 62 refractory metastatic colorectal cancer 62 dose dose escalation 62 sNDA submission 62 BCR ABL inhibitor 62 oxymorphone ER 62 T DM1 62 By JENNIFER LEARN 62 ENMD # 62 Maribavir 62 IMPDH inhibitor 62 CYC# 62 CLL8 62 SYMMETRY trial 62 Belimumab 62 dextofisopam 62 MEK inhibitors 62 ZYBRESTAT TM 62 trial evaluating PRX# 62 small molecule Hedgehog 62 generation Hsp# inhibitor 62 FUSILEV ® 62 Phase III psoriasis 62 SinuNase 62 Entereg R 62 MGd 62 darapladib 62 Patient Enrollment 62 LHRH antagonist 62 ZADAXIN ® 62 voreloxin 62 GMX# 62 Zybrestat 62 ARDIS 62 PRX # 62 Adjuvant Therapy 62 generation proteasome inhibitor 62 OMP #M# 62 Onconase 62 refractory CLL 62 AeroLEF TM 62 PHASE III 62 midstage studies 62 Vernakalant 62 Onrigin 62 Hormone Refractory Prostate Cancer 62 Phase III HEAT 62 refractory Hodgkin lymphoma 62 generation antisense 62 VNP#M 62 MOZOBIL 62 folinic acid FA 62 talabostat 62 MyVax ® 62 TG# [001] 62 FTY# 62 heavily pretreated 62 angiogenesis inhibitor 62 Nexavar sorafenib 62 blinded randomized placebo controlled 62 IIa clinical trial 62 Hsp# inhibitor tanespimycin 62 BioNumerik 62 Initiates Phase 62 modified glutathione analog 62 TO AVOID PREGNANCY WHILE 62 PEG Interferon lambda 62 DPP4 inhibitor 62 DB# [003] 62 sodium Injection 62 sodium thiosulfate STS 62 NU# [001] 62 Telik logo TELINTRA 62 Rezular 62 Begins Dosing 62 monoclonal antibody conjugated 62 candidate XP# 62 IIa clinical 61 XL# SAR# 61 Phase 1b Clinical Trial 61 Severe Sepsis 61 systemic RNAi therapeutic 61 RGB # 61 stage IIIB 61 pegylated liposomal doxorubicin 61 PREOS R 61 Atiprimod 61 EGFR expressing mCRC 61 Lodotra TM 61 demonstrated antitumor activity 61 cariprazine 61 refractory indolent non 61 aplindore 61 XL# XL# XL# 61 Fast Track Status 61 controlled multicenter Phase 61 CIMZIA ™ 61 ThermoDox ® 61 confirmatory pivotal 61 pivotal bioequivalence 61 hepatitis C HCV 61 Exherin TM 61 Myocet 61 KRYSTEXXA TM pegloticase 61 GRASPA ® 61 Locteron

Back to home page